Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novavax Omicron and Bivalent COVID-19 Booster Study
NCT05372588Phase 3Completed
- Sponsor
- Novavax
- Start
- May 2022
- Primary completion
- Jul 2022
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of NVX-CoV2515 and NVX-CoV2540 in coronavirus disease 2019 (COVID-19) (8 arms), sponsored by Novavax. Primary endpoints: MN50 Geometric Mean Titers to Omicron BA.1 Subvariant at Day 14, MN50 Seroresponse Rates to Omicron BA.1 Subvariant at Day 14 and 3 more. Started May 2022; status: completed.
02
Drugs
NVX-CoV2515NVX-CoV2540
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05372588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05372588.